COMP <GO>
EQT vs CVX // EV/EBITDA & P/E VALUATION
EQT Corporation (NYSE) VS. Chevron Corporation (NYSE) • 15-METRIC TALLY: EQT 10
— CVX 4
▲ EV/EBITDA & P/E VALUATION LEADER: EQT
LAST: $54.54 (-2.99%) • MKT CAP: $34.12B
valuation
8.0x
LAST: $231.46 (+0.99%) • MKT CAP: $457.31B
valuation
21.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EQT VS. CVX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EQT | CVX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 82.30% | 41.30% | +41.00 | EQT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.30% | 5.80% | +2.50 | EQT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 8.0x | 21.5x | -13.50 | EQT | /valuation <GO> |
| Free Cash Flow Yield | 8.32% | 5.61% | +2.71 | EQT | /fcf-yield <GO> |
| Operating Margin | 37.60% | 8.10% | +29.50 | EQT | /operating-margins <GO> |
| Net Profit Margin | 23.60% | 6.70% | +16.90 | EQT | /net-margins <GO> |
| Revenue Growth (YoY) | 63.90% | -4.60% | +68.50 | EQT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.14% | 2.79% | -1.65 | CVX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.01 | 3.71 | -1.70 | CVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | EQT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.2 | 64.7 | -11.50 | CVX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.14 | 1.07 | +0.07 | EQT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 14.0x | 34.6x | -20.60 | EQT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $34.12B | $457.31B | -$423.19B | CVX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EQT REV | CVX REV | EQT GROSS % | CVX GROSS % | EQT FCF | CVX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.64B | $184.43B | 82.3% | 41.3% | $2.84B | $25.64B |
| FY 2024 | $5.27B | $193.41B | 63.7% | 38.4% | $573.3M | $22.79B |
| FY 2023 | $5.04B | $196.91B | — | — | $2.95B | $26.75B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EQT // BETA 1.14
CVX // BETA 1.07